BACKGROUND: There is growing evidence that long-term, heavy cannabis use is associated with alterations in regional brain volumes. Although these changes are frequently attributed to the neurotoxic effects of cannabis, it is possible that some abnormalities might predate use and represent markers of vulnerability. To date, no studies have examined whether structural brain abnormalities are present before the onset of cannabis use. This study aims to determine whether adolescents who have initiated cannabis use early (i.e., before age 17 years) show premorbid structural abnormalities in the amygdala, hippocampus, orbitofrontal cortex, and anterior cingulate cortex. METHODS: Participants (n = 121) were recruited from primary schools in Melbourne, Australia, as part of a larger study examining adolescent emotional development. Participants underwent structural magnetic resonance imaging at age 12 years and were assessed for cannabis use 4 years later, at age 16 years. At the follow-up assessment, 28 participants had commenced using cannabis (16 female subjects [57%]), and 93 had not (43 female subjects [46%]). RESULTS: Smaller orbitofrontal cortex volumes at age 12 years predicted initiation of cannabis use by age 16 years. The volumes of other regions (amygdala, hippocampus, and anterior cingulate cortex) did not predict later cannabis use. CONCLUSIONS: These findings suggest that structural abnormalities in the orbitofrontal cortex might contribute to risk for cannabis exposure. Although the results have important implications for understanding neurobiological predictors of cannabis use, further research is needed to understand their relationship with heavier patterns of use in adulthood as well as later abuse of other substances.
BACKGROUND: There is growing evidence that long-term, heavy cannabis use is associated with alterations in regional brain volumes. Although these changes are frequently attributed to the neurotoxic effects of cannabis, it is possible that some abnormalities might predate use and represent markers of vulnerability. To date, no studies have examined whether structural brain abnormalities are present before the onset of cannabis use. This study aims to determine whether adolescents who have initiated cannabis use early (i.e., before age 17 years) show premorbid structural abnormalities in the amygdala, hippocampus, orbitofrontal cortex, and anterior cingulate cortex. METHODS:Participants (n = 121) were recruited from primary schools in Melbourne, Australia, as part of a larger study examining adolescent emotional development. Participants underwent structural magnetic resonance imaging at age 12 years and were assessed for cannabis use 4 years later, at age 16 years. At the follow-up assessment, 28 participants had commenced using cannabis (16 female subjects [57%]), and 93 had not (43 female subjects [46%]). RESULTS: Smaller orbitofrontal cortex volumes at age 12 years predicted initiation of cannabis use by age 16 years. The volumes of other regions (amygdala, hippocampus, and anterior cingulate cortex) did not predict later cannabis use. CONCLUSIONS: These findings suggest that structural abnormalities in the orbitofrontal cortex might contribute to risk for cannabis exposure. Although the results have important implications for understanding neurobiological predictors of cannabis use, further research is needed to understand their relationship with heavier patterns of use in adulthood as well as later abuse of other substances.
Authors: I K Lyoo; S Yoon; T S Kim; S M Lim; Y Choi; J E Kim; J Hwang; H S Jeong; H B Cho; Y A Chung; P F Renshaw Journal: Mol Psychiatry Date: 2015-02-10 Impact factor: 15.992
Authors: Olivier J Barthelemy; Mark A Richardson; Timothy C Heeren; Clara A Chen; Jane M Liebschutz; Leah S Forman; Howard J Cabral; Deborah A Frank; Ruth Rose-Jacobs Journal: J Stud Alcohol Drugs Date: 2019-01 Impact factor: 2.582
Authors: Michael D De Bellis; Lihong Wang; Sara R Bergman; Richard H Yaxley; Stephen R Hooper; Scott A Huettel Journal: Drug Alcohol Depend Date: 2013-06-14 Impact factor: 4.492
Authors: Joanna Jacobus; Lindsay M Squeglia; M Alejandra Infante; Norma Castro; Ty Brumback; Alejandro D Meruelo; Susan F Tapert Journal: Neuropsychology Date: 2015-05-04 Impact factor: 3.295
Authors: Rajendra A Morey; Courtney C Haswell; Stephen R Hooper; Michael D De Bellis Journal: Neuropsychopharmacology Date: 2015-07-14 Impact factor: 7.853
Authors: Francesca M Filbey; Sina Aslan; Vince D Calhoun; Jeffrey S Spence; Eswar Damaraju; Arvind Caprihan; Judith Segall Journal: Proc Natl Acad Sci U S A Date: 2014-11-10 Impact factor: 11.205
Authors: J Cobb Scott; Adon F G Rosen; Tyler M Moore; David R Roalf; Theodore D Satterthwaite; Monica E Calkins; Kosha Ruparel; Raquel E Gur; Ruben C Gur Journal: Neuropsychopharmacology Date: 2019-02-19 Impact factor: 7.853
Authors: Joan L Luby; Arpana Agrawal; Andy Belden; Diana Whalen; Rebecca Tillman; Deanna M Barch Journal: Am J Psychiatry Date: 2018-03-21 Impact factor: 18.112
Authors: Ali Cheetham; Nicholas B Allen; Sarah Whittle; Julian Simmons; Murat Yücel; Dan I Lubman Journal: Psychopharmacology (Berl) Date: 2014-02-20 Impact factor: 4.530